Q-omics provides the consensus-scored SPATA20P1 profile across patient tissues and cancer cell-line models. SPATA20P1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SPATA20P1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, SPATA20P1 RNA expression shows 20,090 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where SPATA20P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA20P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA20P1 survival associations across molecular data types. SPATA20P1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA20P1 RNA expression–survival associations across cancer types. High SPATA20P1 expression shows unfavorable associations in ACC, STAD and HNSC, but favorable associations in SKCM, KIRC and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SPATA20P1 RNA expression.
This table summarizes SPATA20P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA20P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA20P1 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRP, BRCA, COAD and UCEC. The HNSC box plot shows higher SPATA20P1 RNA expression in tumor versus normal tissue (log2 FC = +0.910, t-test p < 0.001).
This table shows molecular features associated with SPATA20P1 in patient tissues and cancer cell lines. In patient samples, SPATA20P1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
